Creatd Sells 80% Stake in Fly Flyte for $6 Million Cash

Creatd, Inc. (CRTD) has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, to Catheter Precision (VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Creatd as a significant shareholder in VTAK. The NYSE-listed VTAK equity becomes part of Creatd's growing portfolio of public and private positions across diversified industries, supported by its technology and AI-first operational infrastructure. Creatd helps companies overcome structural hurdles and mature into institutionally viable enterprises. Creatd acquired Flyte approximately one year ago, after initiating due diligence in Q4 2024, and implemented a disciplined turnaround strategy built around operational optimization, technology integration, and targeted revenue growth, while positioning the company for acquisition by a nationally-listed platform. Creatd initially acquired its position in Flyte using a combination of financing and its then OTC Pink Sheet common stock, whereas the premium exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.